Last reviewed · How we verify

NCT04078425

Non Invasive Assessment of Heart Failure

Status unknown EARLY_PHASE1 Last updated 9 January 2020
What this trial tests

EARLY_PHASE1 trial testing Aldosterone Antagonists in Heart Failure in 100 participants. Status unknown.

Timeline
1 March 2020
Primary endpoint
1 March 2022
1 May 2022

Quick facts

Lead sponsorAssiut University
PhaseEARLY_PHASE1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment100
Start date1 March 2020
Primary completion1 March 2022
Estimated completion1 May 2022

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 18 to 75, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. To Identify the role of aldosterone antagonist in patients of heart failure with preserved ejection fraction. 2. Portray the health profile of heart failure patients admitted in internal medicine department either heart failure with reduced ejection fraction or heart failure with preserved ejection fraction. 3. To compare between patients of right and left sided heart failure by biomarkers and parameters of echocardiographgy 4. Vitamin D and its relation to cardiovascular disease and heart failure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04078425.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing